Rising Toll of Antibiotic-Resistant Infections Costs Thousands of Lives and Billions in Healthcare Dollars Annually

he Partnership to Fight Infectious Disease (PFID) has released new data, analysis and projections into 2035 on the human and economic toll of antimicrobial resistance (AMR), specifically related to hospital-acquired infections. The data show that treating people who acquired AMR infections in healthcare settings incurred costs of $5.8 billion in direct medical care and another $7.2 billion in economic losses relating to premature death. PFID worked with GlobalData Plc on the analysis, which has yielded both national and state fact sheets highlighting the impact of AMR, what’s truly at stake and policy opportunities, like the PASTEUR Act, to better address this increasing public health emergency.